mAb
-
8 Key Highlights! What Do Global Pharma Industry BD and M&A Trends Forecast for 2024?
Where Pharma is Investing for the Future of Medicine: Biopharma Deal Making in 2024
-
ANTI-CDCP1 mAb and ADC 【Product for Licensing】
If interested, please contact DrugTimes BD Team at BD@drugtimes.cn. We will discuss with you and may present the non-confidential deck to you for review asap.
-
A long-acting anti-TL1A mAb with best-in-class potential
If you are interested in this product, please contact us at BD@drugtimes.cn, we will send the non-confidential deck to you for review
-
AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease
If you are looking for a promising TL1A product, please contact DrugTimes BD Team (BD@drugtimes.cn)
